ProQR to Present at Scientific and Investor Conferences in September
Sep 06, 2016 11:01 am UTC| Business
LEIDEN, the Netherlands, Sept. 06, 2016 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases...
Syndax Pharmaceuticals Announces Participation at Four Upcoming Investor Conferences
Sep 06, 2016 11:01 am UTC| Business
WALTHAM, Mass., Sept. 06, 2016 -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its...
Plug Power Confirms Investor Conference Schedule for September 2016
Sep 06, 2016 11:01 am UTC| Business
LATHAM, N.Y., Sept. 06, 2016 -- Plug Power Inc. (NASDAQ:PLUG), a leader in providing energy solutions that change the way the world moves, today confirms its investor conference schedule for September 2016. The Plug...
Plug Power Confirms Investor Conference Schedule for September 2016
Sep 06, 2016 11:01 am UTC| Business
LATHAM, N.Y., Sept. 06, 2016 -- Plug Power Inc. (NASDAQ:PLUG), a leader in providing energy solutions that change the way the world moves, today confirms its investor conference schedule for September 2016. The Plug...
Sep 06, 2016 11:01 am UTC| Business
BERKELEY HEIGHTS, N.J., Sept. 06, 2016 -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target various phases of...
Axsome Therapeutics to Present at Upcoming Investor Conferences
Sep 06, 2016 11:00 am UTC| Business
NEW YORK, Sept. 06, 2016 -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced...
Sep 06, 2016 11:00 am UTC| Business
- Selinexor Achieves Promising Response Rates in Patients with Multiple Myeloma, Including 20.8% in Quad-Refractory and 20.0% in Penta-Refractory Disease - - Expanding Phase 2b STORM Study to Include Approximately 120...